Psyence Biomedical Ltd
PBM1.000USD
-0.460-31.51%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
1.87MMarket Cap
LossP/E TTM
More Details of Psyence Biomedical Ltd Company
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Psyence Biomedical Ltd Info
Ticker SymbolPBM
Company namePsyence Biomedical Ltd
IPO dateDec 10, 2021
CEOMaresky (Neil)
Number of employees12
Security typeOrdinary Share
Fiscal year-endDec 10
Address121 Richmond Street West Penthouse
CityTORONTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeM5H 2K1
Phone17744604171
Website
Ticker SymbolPBM
IPO dateDec 10, 2021
CEOMaresky (Neil)
Company Executives of Psyence Biomedical Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 13
Updated: Sat, Dec 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
KAOS Capital Ltd
16.77%
Parallel Advisors, LLC
8.08%
White Lion Capital LLC
0.67%
Virtu Americas LLC
0.55%
AdvisorShares Investments, LLC
0.29%
Other
73.65%
Shareholders
Shareholders
Proportion
KAOS Capital Ltd
16.77%
Parallel Advisors, LLC
8.08%
White Lion Capital LLC
0.67%
Virtu Americas LLC
0.55%
AdvisorShares Investments, LLC
0.29%
Other
73.65%
Shareholder Types
Shareholders
Proportion
Corporation
16.95%
Investment Advisor
8.64%
Research Firm
0.73%
Venture Capital
0.70%
Other
72.98%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
38
319.64K
17.07%
+174.04K
2025Q2
45
357.80K
50.17%
+181.11K
2025Q1
45
167.96K
26.60%
+69.68K
2024Q4
82
948.20K
24.27%
+587.08K
2024Q3
88
169.92K
15.90%
-186.51K
2024Q2
92
159.62K
36.84%
-203.47K
2024Q1
96
157.41K
35.61%
-211.56K
2023Q4
88
18.95K
16.18%
-253.66K
2023Q3
87
16.58K
55.18%
-252.44K
2023Q2
86
17.96K
50.97%
-264.02K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Parallel Advisors, LLC
275.00K
38.56%
+275.00K
--
Jun 30, 2025
White Lion Capital LLC
12.55K
1.76%
+12.55K
--
Dec 04, 2024
Virtu Americas LLC
--
0%
-4.58K
-100.00%
Jun 30, 2025
AdvisorShares Investments, LLC
4.45K
0.62%
-1.00
-0.02%
Jun 30, 2025
BofA Global Research (US)
3.34K
0.47%
+3.34K
--
Jun 30, 2025
Launchpad Ignition Holdings LLC
2.00K
0.28%
+2.00K
--
Mar 31, 2024
Tabula Rasa Ltd
1.45K
0.2%
-728.00
-33.47%
Mar 31, 2024
Stonehage Fleming Financial Services Holdings, Ltd.
561.00
0.08%
-1.00
-0.18%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
0%
AdvisorShares Psychedelics ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 01, 2025
Merger
7.97→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Date
Type
Ratio
May 01, 2025
Merger
7.97→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
FAQs
Who are the top five shareholders of Psyence Biomedical Ltd?
The top five shareholders of Psyence Biomedical Ltd are:
Parallel Advisors, LLC holds 275.00K shares, accounting for 38.56% of the total shares.
White Lion Capital LLC holds 12.55K shares, accounting for 1.76% of the total shares.
Virtu Americas LLC holds 0.00 shares, accounting for 0.00% of the total shares.
AdvisorShares Investments, LLC holds 4.45K shares, accounting for 0.62% of the total shares.
BofA Global Research (US) holds 3.34K shares, accounting for 0.47% of the total shares.
Parallel Advisors, LLC holds 275.00K shares, accounting for 38.56% of the total shares.
White Lion Capital LLC holds 12.55K shares, accounting for 1.76% of the total shares.
Virtu Americas LLC holds 0.00 shares, accounting for 0.00% of the total shares.
AdvisorShares Investments, LLC holds 4.45K shares, accounting for 0.62% of the total shares.
BofA Global Research (US) holds 3.34K shares, accounting for 0.47% of the total shares.
What are the top three shareholder types of Psyence Biomedical Ltd?
The top three shareholder types of Psyence Biomedical Ltd are:
KAOS Capital Ltd
Parallel Advisors, LLC
White Lion Capital LLC
KAOS Capital Ltd
Parallel Advisors, LLC
White Lion Capital LLC
How many institutions hold shares of Psyence Biomedical Ltd (PBM)?
As of 2025Q3, 38 institutions hold shares of Psyence Biomedical Ltd, with a combined market value of approximately 319.64K, accounting for 17.07% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -33.09%.
What is the biggest source of revenue for Psyence Biomedical Ltd?
In --, the -- business generated the highest revenue for Psyence Biomedical Ltd, amounting to -- and accounting for --% of total revenue.
